NX-019 / Nalo Therap  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NX-019 / Nalo Therap
NCT05514496: A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

Recruiting
1
258
US, RoW
NX-019
Nalo Therapeutics Inc.
EGFR Mutation-Related Tumors
02/27
10/27

Download Options